COR VS TAK Stock Comparison
Performance
COR100/100
100/100
COR returned 7.05% in the last 12 months. Based on SPY's performance of -13.80%, its performance is above average giving it a score of 100 of 100.
TAK10/100
10/100
TAK returned 0.51% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
COR68/100
68/100
15 analysts offer 12-month price targets for COR. Together, they have an average target of 171, the most optimistic target put COR at 190 within 12-months and the most pessimistic has COR at 150.
TAK
"Analyst Price Targets" not found for TAK
Earnings
COR100/100
100/100
COR has missed earnings 1 times in the last 20 quarters.
TAK14/100
14/100
TAK has missed earnings 3 times in the last 20 quarters.
Profit
COR84/100
84/100
Out of the last 20 quarters, COR has had 20 profitable quarters and has increased their profits year over year on 12 of them.
TAK71/100
71/100
Out of the last 20 quarters, TAK has had 16 profitable quarters and has increased their profits year over year on 9 of them.
Volatility
COR55/100
55/100
COR has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.
TAK61/100
61/100
TAK has had a higher than average amount of volatility over the last 12 months giving it a score of 60 of 100.
Dividend
COR10/100
10/100
COR's most recent dividend was $0.81 per share, based on a share price of $193.22. It was a payout ratio of 182.09% compared to their total earnings.
TAK
"Dividend" not found for TAK
Technicals
COR
"Technicals" not found for COR
TAK36/100
36/100
TAK receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.
All score calculations are broken down here to help you make more informed investing decisions
Cencora, Inc. Summary
New York Stock Exchange / COR
Healthcare
Medical - Distribution
Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) Summary
New York Stock Exchange / TAK
Healthcare
Drug Manufacturers - Specialty & Generic
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare COR to other companies in the same or a similar industry.